KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Other financing activities: 2012-2016

  • Novavax's Other financing activities was N/A to $10.0 million in Q1 2016 from the same period last year, while for Mar 2016 it was $9.8 million, marking a year-over-year change of. This contributed to the annual value of $10.0 million for FY2016, which is 8009.52% up from last year.
  • Novavax's Other financing activities amounted to $10.0 million in Q1 2016, which was up 8,009.52% from -$126,000 recorded in Q3 2015.
  • Novavax's 5-year Other financing activities high stood at $10.0 million for Q1 2016, and its period low was -$755,000 during Q1 2012.
  • Its 3-year average for Other financing activities is $2.5 million, with a median of -$1,000 in 2014.
  • Data for Novavax's Other financing activities shows a peak YoY surged of 99.87% (in 2013) over the last 5 years.
  • Quarterly analysis of 5 years shows Novavax's Other financing activities stood at -$1,000 in 2012, then surged by 99.87% to -$1,000 in 2013, then remained steady at -$1,000 in 2014, then reached -$126,000 in 2015, then reached $10.0 million in 2016.
  • Its Other financing activities was $10.0 million in Q1 2016, compared to -$126,000 in Q3 2015 and -$1,000 in Q4 2014.